Reach the right stakeholders with the right message at launch and beyond at Nexus 2025.

Position your pipeline in front of managed care decision-makers while preparing for regulatory milestones at Nexus 2025.

Start building relationships with health care decision-makers before you have a product on the market at Nexus 2025.

Explore how your company can engage with managed care decision-makers (HCDMs) at every stage of the product lifecycle—from emerging brand to pre-approval and product launch. Our lifecycle flow highlights Nexus 2025 opportunities, digital amplification, educational platforms, and thought leadership touchpoints to build awareness, credibility, and adoption.

Policymakers frequently target pharmacy benefit managers (PBMs) in a well-meaning attempt to contain rising drug prices, but some proposed changes could have the opposite effect for patients. AMCP encourages PBM reform efforts to focus on common-sense requirements for transparency reporting by PBMs. It’s time for a more nuanced discussion about PBM reform—one that lowers the temperature and puts patients first.

Prescription digital therapeutics (PDTs) are software-based therapies shown to benefit those with mental health conditions like depression. However, many PDTs do not currently fit into one of the statutorily defined coverage categories for the Medicare or Medicaid programs, leaving beneficiaries of those programs—which include some of America’s most vulnerable populations—without access to these effective and accessible treatments. AMCP supports the Access to Prescription Digital Therapeutics Act, an important bipartisan bill that would help remedy this disparity by creating a comprehensive benefit category and expanding Medicare coverage to include PDTs.

Signed into law in 2022, the Inflation Reduction Act (IRA) ushered in Medicare prescription drug pricing reforms and imposed caps on out-of-pocket expenses for Part D beneficiaries. While much discussion and analysis has focused on how the IRA will impact Medicare beneficiaries, Part D plans, and government spending, the impact of the legislation will extend to stakeholders across the U.S. health care industry.